The future of biological agents in the treatment of rheumatoid arthritis

Charlotte Rawlings; Ernest Choy

首页> 外文期刊>International journal of clinical rheumatology. >The future of biological agents in the treatment of rheumatoid arthritis

【24h】

The future of biological agents in the treatment of rheumatoid arthritis

机译：生物制剂在类风湿关节炎治疗中的未来

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Rheumatoid arthritis (RA) is an autoimmune disease with a currently unknown etiology and multifactorial pathogenesis. This review recaps on the history of development of the main principles of biological disease-modifying agents. Moving into current treatment guidance from Europe and the USA, monotherapy and second-line biological choice is addressed. The reviews explores and summarizes the latest developments and potential impact of anti-cytokine therapy, including TNF, IL-6 and IL-17, anti-lymphocyte therapies, B cell modulators and other B-cell targets, anti-CD3, biosimilars and finally oral agents such as JAK and Syk inhibitors.

机译：类风湿关节炎（RA）是一种自身免疫性疾病，其病因和多因素发病机制目前未知。这篇综述回顾了生物疾病改良剂主要原理的发展历史。进入欧洲和美国的当前治疗指南后，解决了单一疗法和二线生物学选择问题。综述探讨并总结了抗细胞因子疗法的最新发展及其潜在影响，包括TNF，IL-6和IL-17，抗淋巴细胞疗法，B细胞调节剂和其他B细胞靶标，抗CD3，生物仿制药，最后口服药物，例如JAK和Syk抑制剂。

著录项

来源
《International journal of clinical rheumatology.》 |2014年第5期|共12页
作者
Charlotte Rawlings; Ernest Choy;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类全身性疾病;
关键词
biologic; disease-modifying antirheumatic drugs; JAK inhibitor; rheumatoid arthritis; TNF inhibitors;

机译：生物;疾病抗风湿药;JAK抑制剂;类风湿关节炎;TNF抑制剂;

相似文献

外文文献
中文文献
专利

1. The future of biological agents in the treatment of rheumatoid arthritis [J] . Charlotte Rawlings, Ernest Choy International journal of clinical rheumatology. . 2014,第5期

机译：生物制剂在类风湿关节炎治疗中的未来
2. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. [J] . Genovese MC, Kavanaugh A, Weinblatt ME, Arthritis and Rheumatism . 2011,第2期

机译：口服Syk激酶抑制剂治疗类风湿性关节炎：为期3个月的随机，安慰剂对照，II期研究，用于对生物制剂无反应的活动性类风湿性关节炎患者。
3. Rheumatoid arthritis: Lower work loss during treatment with biologicals? - Modern treatment principles reduce work loss in rheumatoid arthritis [Rheumatoide Arthritis: Geringerer Arbeitszeitausfall bei Therapie mit Biologicals? - Moderne Therapieprinzipien reduzieren Arbeitsunf? higkeitstage bei rheumatoider Arthritis] [J] . KrügerK. DMW: Deutsche Medizinische Wochenschrift . 2013,第44期

机译：类风湿关节炎：用生物制剂治疗期间工作量减少了吗？ -现代治疗原则可减少类风湿关节炎的工作损失[类风湿性关节炎：使用生物制剂进行治疗时减少的工作时间减少了吗？ -现代治疗原则可减少工作事故？类风湿关节炎的工作日]
4. Exploring potential therapeutic agents of Duhuo-Jisheng-Tang for rheumatoid arthritis [C] . Guang Zheng, Tong Wei, Changsheng Ma, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：探索度活吉生汤治疗类风湿关节炎的潜在治疗剂
5. Predictors of Infection in Rheumatoid Arthritis Patients Using Anti-Tumor Necrosis Factor Agents [D] . Liu, Tasia 2017

机译：类风湿关节炎患者使用抗肿瘤坏死因子药物的感染预测因子
6. Monitoring Drug and Antidrug Levels: A Rational Approach in Rheumatoid Arthritis Patients Treated with Biologic Agents Who Experience Inadequate Response While Being on a Stable Biologic Treatment [O] . Diana Mazilu, Daniela Opriş, Cecilia Gainaru, -1

机译：监测药物和抗药物水平：类风湿性关节炎患者的合理方法是在接受稳定的生物治疗时遇到反应不足的生物制剂
7. Results of cross-sectional epidemiologic study on determination of recombinant biological agents requirement for treatment of patients with rheumatoid arthritis in real-life clinical practice. Report 1. Demographic, social, clinicaland laboratory characteristics of Russian patients with rheumatoid arthritis [O] . S F Erdes, O M Folomeeva, E A Galishko, 2009

机译：真生临床实践中类风湿性关节炎患者治疗重组生物学试剂的横截面流行病学研究的结果。报告1.俄罗斯类风湿性关节炎患者的人口，社会，临床实验室特征

The future of biological agents in the treatment of rheumatoid arthritis

摘要

著录项

相似文献

相关主题

期刊订阅